New quality standards from NICE create opportunities to support research
NICE (The National Institute for Health and Care Excellence) has determined 5 draft quality statements designed to improve the standard of diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. The standards describe high-quality care in priority areas for improvement.
This also gives us – our community at brainstrust – a great opportunity to help NICE assess the relevance and potential issues surrounding these statements. Following the statements are 5 questions for the community to respond to. Answering these questions will help refine the quality statements and therefore help NICE focus on the needs of the community even more.
The quality statements determined by NICE:
- Statement 1. GPs have direct access to standard MRI for adults who have suspected brain tumour.
- Statement 2. Adults with brain tumours have a named healthcare professional who coordinates their health and social care support.
- Statement 3 .Adults with radiologically enhancing suspected high-grade gliomas that are suitable for resection of all enhancing tumour have 5‑ALA guided resection.
- Statement 4. Adults who finish treatment for brain tumours have an assessment and discussion about the risk of late effects of treatment at their first follow-up appointment.
- Statement 5. Adults with brain tumours can access neurological rehabilitation assessment in the community.
Questions for consultation:
Question 1) Do you feel this draft quality standard accurately reflect the key areas
for quality improvement?
Question 2) Do you think local systems and structures are in place to collect data for the
proposed quality measures? If not, how feasible do you think it would be for these to be
put in place?
Question 3) Do you think each of the statements in this draft quality
standard would be achievable by local services given the resources
needed to deliver them? Please describe any resource requirements that
you think would be necessary for any statement.
Question 4) For draft quality statement 4: Do you feel it’s feasible to carry out an
assessment and discussion about the risk of late effects of treatment at the
first follow-up appointment after treatment? If not, please say why and if
possible, could you suggest an alternative timescale?
Question 5) For draft quality statement 5: Stakeholders have highlighted
the need to improve access to neurological rehabilitation for adults with
brain tumours. Do you think this is the right focus for this statement? If not, please
identify what you feel the right focus is.
If you would like to help NICE refine its statements and provide your insight and views, please send responses to these 5 questions to Adam at brainstrust: firstname.lastname@example.org
If you’re living with a brain tumour and have any questions around this latest news, or want to access support, give us a call on 01983 292 405 or email email@example.com